Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)

Schering-Plough

Status: Completed

Conditions: Hepatitis C, Chronic; Hepacivirus

Treatments: Drug: Ribavirin (SCH 18908); Biological: Peginterferon alfa-2b (SCH 54031)

Study type: Observational

Funder types: Industry

Identifiers

NCT00705263

P04244

Details and patient eligibility

About

The current gold standard for treatment of chronic hepatitis C is pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegIntron pen (PegPen). Therefore, it is worthwhile to evaluate patients' satisfaction with this novel device. The results of the study will be used to improve PegPen training techniques for patients and health care providers.

Enrollment: 113 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic hepatitis C treated with the PegIntron pen plus Rebetol

Exclusion criteria

• Not willing to participate in the study

Trial design

113 participants in 1 patient group

Patients with chronic hepatitis C

Description:

Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.

Treatment:

Biological: Peginterferon alfa-2b (SCH 54031)

Drug: Ribavirin (SCH 18908)